GlobalData offers a comprehensive analysis of Recursion Pharmaceuticals, providing key insights into its Environmental, Social, and Governance(ESG) factors. By closely monitoring and aggregating mentions of Net Zero and associated ESG keywords, GlobalData delivers valuable information on Recursion Pharmaceuticals‘s ESG performance. GlobalData’s company profile on Recursion Pharmaceuticals offers a 360-degree view of the company, SWOT analysis, key financials, and business strategy including insights on ESG implementation among other information. Buy the report here.
Smarter leaders trust GlobalData
Recursion Pharmaceuticals has committed to achieving net-zero greenhouse gas emissions by 2030, according to its 2023 ESG report. The company plans to invest in renewable energy sources and net-zero greenhouse gas data centers to achieve this goal. Recursion Pharmaceuticals’ latest filings mentioned the keywords 'Emissions' and 'Carbon Emissions' most number of times in relation to ‘Net-Zero’.
Recursion Pharmaceuticals' cloud computing gross carbon emissions increased from 263.5 MTCO2E in 2021 to 294.8 MTCO2E in 2022, while its net emissions decreased from 24.4 MTCO2E to 3 MTCO2E. In 2022, the company reported its Scope 1 Greenhouse Gas Inventory emissions at 269.26 Metric Tons Co2e and Scope 2 (market based) Greenhouse Gas Inventory emissions at 980.32 Metric Tons Co2e.
Recursion Pharmaceuticals has taken steps to reduce its emissions, including investing in renewable energy sources and using energy-efficient practices in its data centers. The company has also migrated several large databases to a third-party provider, which has helped to drive down net carbon emissions. Recursion Pharmaceuticals has achieved nearly 100% net-zero carbon in its cloud operations. The company also tracks its waste metrics and has implemented waste management programs to recycle appropriate materials generated in its office and laboratory.
In conclusion, Recursion Pharmaceuticals has committed to achieving net-zero greenhouse gas emissions by 2030. The company has taken steps to reduce its emissions, including investing in renewable energy sources and using energy-efficient practices in its data centers. Recursion Pharmaceuticals has achieved nearly 100% net-zero carbon in its cloud operations and tracks its waste metrics to ensure responsible management of both hazardous and nonhazardous office and laboratory waste.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies representing the world’s largest industries. This analysis is combined with crucial details on strategic and investment priorities, innovation strategies, and CXO insights to provide comprehensive company profiles.
